Novartis stock falls 10% after second drug setback in a week; analyst cuts PT
Covered by 1 source · 1 article
Novartis shares fell sharply on Tuesday after the Swiss drugmaker said its experimental treatment for myotonic dystrophy failed in a late-stage clinical trial, marking another setback for a pipeline that investors had been counting on to dr…
Covered by
